Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Allogeneic stem cell transplantation for aplastic anemia.

Philippe Armand1, Joseph H Antin

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA. parmand@partners.org

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|April 24, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Preemptive hematopoietic stem cell transplantation in <i>RUNX1</i> familial platelet disorder: a shared decision-making framework.

Haematologica·2026
Same author

Impact of Post-Transplant Cyclophosphamide on the Prognostic Value of HCT-CI.

Transplantation and cellular therapy·2026
Same author

No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

Blood advances·2026
Same author

Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Blood advances·2026
Same author

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Blood advances·2025

Severe aplastic anemia treatment involves immunosuppressive therapy (IST) or hematopoietic stem cell transplantation (HSCT). This review details advances in HSCT and provides a framework for choosing front-line therapy.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Aplastic anemia is a rare bone marrow failure disorder.
  • Severe aplastic anemia (SAA) necessitates timely and effective treatment.
  • Treatment options include immunosuppressive therapy (IST) and hematopoietic stem cell transplantation (HSCT).

Purpose of the Study:

  • To review advancements in HSCT for aplastic anemia over the past 30 years.
  • To present a framework for selecting patients for upfront HSCT versus IST.
  • To address the evolving therapeutic landscape of SAA.

Main Methods:

  • Review of scientific literature on aplastic anemia treatment.
  • Analysis of outcomes data for IST and HSCT.
  • Development of a clinical decision-making framework.

Related Experiment Videos

Main Results:

  • Significant improvements in HSCT efficacy and safety have been observed.
  • Patient selection criteria for HSCT have evolved.
  • A structured approach can optimize front-line treatment decisions.

Conclusions:

  • HSCT has become a highly effective treatment for SAA, particularly with recent advances.
  • Careful patient stratification is crucial for determining the optimal initial therapy.
  • Further research may refine treatment algorithms for SAA.